◎ Sugi Atlas

Atlas / Gene / AMZ1

AMZ1

gene
On this page

Also known as KIAA1950

Summary

AMZ1 (archaelysin family metallopeptidase 1, HGNC:22231) is a protein-coding gene on chromosome 7p22.3, encoding Archaemetzincin-1 (Q400G9). Probable zinc metalloprotease.

Predicted to enable metal ion binding activity and metallopeptidase activity. Predicted to be involved in proteolysis.

Source: NCBI Gene 155185 — RefSeq curated summary.

At a glance

  • GWAS associations: 69
  • Clinical variants (ClinVar): 217 total — 2 pathogenic
  • Phenotypes (HPO): 1
  • MANE Select transcript: NM_001384743

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:22231
Approved symbolAMZ1
Namearchaelysin family metallopeptidase 1
Location7p22.3
Locus typegene with protein product
StatusApproved
AliasesKIAA1950
Ensembl geneENSG00000174945
Ensembl biotypeprotein_coding
OMIM615168
Entrez155185

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000312371, ENST00000407112, ENST00000433945, ENST00000480560, ENST00000485540, ENST00000489665, ENST00000683327, ENST00000880039, ENST00000880040, ENST00000880041, ENST00000880042, ENST00000954549

RefSeq mRNA: 8 — MANE Select: NM_001384743 NM_001284355, NM_001321766, NM_001384739, NM_001384740, NM_001384741, NM_001384742, NM_001384743, NM_133463

CCDS: CCDS34589, CCDS64582

Canonical transcript exons

ENST00000683327 — 7 exons

ExonStartEnd
ENSE0000118197727090752709244
ENSE0000126434827002342700755
ENSE0000156375826882022688296
ENSE0000347476127085882708716
ENSE0000360269427027222702889
ENSE0000365471827096402709816
ENSE0000391817427123302719683

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 78.25.

FANTOM5 (CAGE): breadth broad, TPM avg 1.8966 / max 33.2578, expressed in 450 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
770271.8966450

Top tissues by expression

227 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
male germ line stem cell (sensu Vertebrata) in testisCL:0000089 ∩ UBERON:000047378.25gold quality
amygdalaUBERON:000187673.99gold quality
stromal cell of endometriumCL:000225573.49gold quality
spermCL:000001973.19gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099171.92gold quality
prefrontal cortexUBERON:000045171.51gold quality
nucleus accumbensUBERON:000188271.23gold quality
sural nerveUBERON:001548871.03gold quality
anterior cingulate cortexUBERON:000983570.97gold quality
midbrainUBERON:000189170.27gold quality
substantia nigraUBERON:000203870.23gold quality
ventricular zoneUBERON:000305370.11gold quality
putamenUBERON:000187469.95gold quality
lateral globus pallidusUBERON:000247669.90silver quality
corpus callosumUBERON:000233669.81gold quality
vena cavaUBERON:000408769.81gold quality
pericardiumUBERON:000240769.78gold quality
superior vestibular nucleusUBERON:000722769.63gold quality
cerebellar vermisUBERON:000472069.51gold quality
body of tongueUBERON:001187669.37gold quality
tongueUBERON:000172369.36gold quality
nippleUBERON:000203069.35gold quality
superior surface of tongueUBERON:000737169.30gold quality
pharyngeal mucosaUBERON:000035569.21gold quality
skeletal muscle tissue of rectus abdominisUBERON:000451169.14gold quality
substantia nigra pars compactaUBERON:000196569.06silver quality
hypothalamusUBERON:000189868.97gold quality
medulla oblongataUBERON:000189668.93gold quality
saphenous veinUBERON:000731868.89gold quality
temporal lobeUBERON:000187168.76gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

ExperimentMarker?Max mean expression
E-ANND-3no2.89

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting AMZ1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-6867-5P100.0082.213464
HSA-MIR-4747-5P100.0067.902681
HSA-MIR-5196-5P100.0067.982761
HSA-MIR-1252-5P100.0069.802774
HSA-MIR-118499.9968.191458
HSA-MIR-607799.9968.042299
HSA-MIR-1229-3P99.9766.49906
HSA-MIR-6825-5P99.9669.813431
HSA-MIR-426799.9666.532368
HSA-MIR-548AJ-3P99.9673.385345
HSA-MIR-548X-3P99.9673.385345
HSA-MIR-185-3P99.9567.011743
HSA-MIR-548AJ-5P99.7871.123085
HSA-MIR-548F-5P99.7871.023093
HSA-MIR-548G-5P99.7871.123085
HSA-MIR-548X-5P99.7871.123085
HSA-MIR-3150A-3P99.7664.441640
HSA-MIR-6763-5P99.7664.681767
HSA-MIR-4766-5P99.7569.232662
HSA-MIR-366099.6867.331149
HSA-MIR-452699.6867.071136
HSA-MIR-6887-3P99.6667.831778
HSA-MIR-10394-5P99.6566.831852
HSA-MIR-120599.6566.761826
HSA-MIR-1287-3P99.6366.93492
HSA-MIR-29899.6367.561916
HSA-MIR-5003-5P99.6169.131624
HSA-MIR-613299.6065.831554
HSA-MIR-6836-5P99.6065.621538
HSA-MIR-18A-3P99.5665.681092

Cross-species orthologs

2 orthologs

OrganismSymbolGene ID
mus_musculusAmz1ENSMUSG00000050022
rattus_norvegicusAmz1ENSRNOG00000077699

Paralogs (1): AMZ2 (ENSG00000196704)

Protein

Protein identifiers

Archaemetzincin-1 — Q400G9 (reviewed: Q400G9)

Alternative names: Archeobacterial metalloproteinase-like protein 1

All UniProt accessions (2): Q400G9, A4D202

UniProt curated annotations — full annotation on UniProt →

Function. Probable zinc metalloprotease.

Cofactor. Binds 2 Zn(2+) ions per subunit. One is catalytic, whereas the other seems to have a structural role.

Similarity. Belongs to the peptidase M54 family.

Isoforms (2)

UniProt IDNamesCanonical?
Q400G9-11yes
Q400G9-22

RefSeq proteins (8): NP_001271284, NP_001308695, NP_001371668, NP_001371669, NP_001371670, NP_001371671, NP_001371672, NP_597720 (=MANE)

Domains & families (InterPro)

IDNameType
IPR012962Pept_M54_archaemetzincnFamily
IPR024079MetalloPept_cat_dom_sfHomologous_superfamily
IPR052009ArchaemetzincinFamily

UniProt features (12 total): binding site 6, splice variant 2, chain 1, region of interest 1, sequence variant 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q400G9-F174.620.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 262 (proton acceptor)

Ligand- & substrate-binding residues (6): 261; 265; 272; 277; 296; 299

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 104 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, chr7p22, NIKOLSKY_BREAST_CANCER_7P22_AMPLICON, BOYLAN_MULTIPLE_MYELOMA_C_D_UP, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, CHEN_METABOLIC_SYNDROM_NETWORK, DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP, DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP, BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP, BHAT_ESR1_TARGETS_VIA_AKT1_UP, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_129_MOUSE_UP, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_IFNAR_KO_UP

GO Biological Process (1): proteolysis (GO:0006508)

GO Molecular Function (4): metallopeptidase activity (GO:0008237), metal ion binding (GO:0046872), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (1): cellular_component (GO:0005575)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
protein metabolic process1
peptidase activity1
cation binding1
hydrolase activity1
catalytic activity, acting on a protein1
catalytic activity1

Protein interactions and networks

STRING

442 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
AMZ1CCDC57Q2TAC2521
AMZ1FASTKD3Q14CZ7512
AMZ1OR6T1Q8NGN1505
AMZ1NKAIN4Q8IVV8493
AMZ1STK31Q9BXU1484
AMZ1RDM1Q8NG50476
AMZ1FAM111AQ96PZ2473
AMZ1CMYA5Q8N3K9461
AMZ1DNAJC12Q9UKB3460
AMZ1DMRT3Q9NQL9457
AMZ1MESP2Q0VG99452
AMZ1FREM2Q5SZK8447
AMZ1KRT75O95678445
AMZ1RASAL1O95294445
AMZ1RAPGEFL1Q9UHV5445

IntAct

4 interactions, top by confidence:

ABTypeScore
AMZ1SUSD5psi-mi:“MI:0914”(association)0.530
AMZ1IFT56psi-mi:“MI:0914”(association)0.350

BioGRID (55): NCKAP1 (Affinity Capture-MS), AIFM1 (Affinity Capture-MS), WASF1 (Affinity Capture-MS), NHSL1 (Affinity Capture-MS), CYFIP2 (Affinity Capture-MS), ABI2 (Affinity Capture-MS), SUSD5 (Affinity Capture-MS), ABI1 (Affinity Capture-MS), POLD2 (Affinity Capture-MS), BRK1 (Affinity Capture-MS), WASF2 (Affinity Capture-MS), CYFIP1 (Affinity Capture-MS), AMZ1 (Positive Genetic), AMZ1 (Affinity Capture-RNA), WASF3 (Affinity Capture-MS)

ESM2 similar proteins: A0JNQ6, A6NC42, A6NGQ2, A6NGR9, A6QP75, A7E3N7, A9X185, E1BDF2, E9PGG2, F6SZT2, P0C7A0, P85965, Q06VW1, Q0ZFW8, Q14DK4, Q3UK37, Q3UV16, Q3ZBN4, Q400G9, Q4VXA5, Q587J8, Q5JSQ8, Q60953, Q60I26, Q60I27, Q6NUI2, Q6ZUX3, Q810I0, Q8BH06, Q8C0R7, Q8IWB1, Q8IWY9, Q8IYX4, Q8K4C2, Q8N6L0, Q8N7F7, Q8NCV1, Q8TE82, Q91WA6, Q95JV3

Diamond homologs: B0R889, Q3ITQ5, Q400C7, Q400C8, Q400C9, Q400G9, Q4R684, Q57729, Q5R4A6, Q5V0J7, Q74M83, Q86W34, Q8BVF9, Q8ZW37, Q9HMC3, Q9YFV3, Q4JB73, Q18KE9, Q5JGD6, Q8TXW1, Q8TZW5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

217 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic2
Likely pathogenic0
Uncertain significance169
Likely benign17
Benign11

Top pathogenic / likely-pathogenic (2)

Variant IDHGVSClassification
3245808NC_000007.13:g.(?2559496)(2998140_?)delPathogenic
443024GRCh37/hg19 7p22.3-22.1(chr7:1201674-5175651)x1Pathogenic

SpliceAI

2736 predictions. Top by Δscore:

VariantEffectΔscore
7:2702718:CCA:Cacceptor_loss1.0000
7:2702719:CAG:Cacceptor_loss1.0000
7:2702720:A:AGacceptor_gain1.0000
7:2702721:G:GTacceptor_gain1.0000
7:2702721:GAC:Gacceptor_gain1.0000
7:2702721:GACC:Gacceptor_gain1.0000
7:2702721:GACCT:Gacceptor_gain1.0000
7:2702889:GGT:Gdonor_loss1.0000
7:2702891:T:Adonor_loss1.0000
7:2708584:GCA:Gacceptor_loss1.0000
7:2708585:CA:Cacceptor_loss1.0000
7:2708586:A:AGacceptor_gain1.0000
7:2708586:AGA:Aacceptor_loss1.0000
7:2708586:AGAC:Aacceptor_gain1.0000
7:2708586:AGACG:Aacceptor_gain1.0000
7:2708587:G:GTacceptor_gain1.0000
7:2708587:GA:Gacceptor_gain1.0000
7:2708587:GAC:Gacceptor_gain1.0000
7:2708587:GACG:Gacceptor_gain1.0000
7:2708587:GACGG:Gacceptor_gain1.0000
7:2709074:GAA:Gacceptor_gain1.0000
7:2731749:TT:Tacceptor_gain1.0000
7:2733445:A:ACdonor_gain1.0000
7:2733446:C:CCdonor_gain1.0000
7:2733450:CCAG:Cdonor_gain1.0000
7:2679668:ACAG:Adonor_loss0.9900
7:2679669:CAG:Cdonor_loss0.9900
7:2679670:AGGTA:Adonor_loss0.9900
7:2679671:GGTAC:Gdonor_loss0.9900
7:2679672:GT:Gdonor_loss0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000052206 (7:2741217 G>A,T), RS1000059208 (7:2684700 AG>A), RS1000060664 (7:2756768 C>A,T), RS1000070205 (7:2755648 A>C), RS1000076842 (7:2723508 T>G), RS1000088734 (7:2688329 C>A,G), RS1000108260 (7:2703240 G>T), RS1000181809 (7:2688137 C>T), RS1000193055 (7:2752681 G>A), RS1000220106 (7:2735292 A>G), RS1000220931 (7:2720127 C>G,T), RS1000250397 (7:2720218 C>G,T), RS1000309060 (7:2727428 G>A,C), RS1000321711 (7:2691811 T>G), RS1000321872 (7:2748375 T>C)

Disease associations

OMIM: gene MIM:615168 | disease phenotypes: MIM:615206, MIM:616452

GenCC curated gene-disease

Mondo (3): severe combined immunodeficiency due to CARD11 deficiency (MONDO:0014081), BENTA disease (MONDO:0014645), obesity disorder (MONDO:0011122)

Orphanet (4): Combined immunodeficiency due to CARD11 deficiency (Orphanet:357237), BENTA disease (Orphanet:464336), Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPOTerm
HP:0001513Obesity

GWAS associations

69 associations (top):

StudyTraitp-value
GCST001956_7Height4.000000e-23
GCST003518_48Daytime sleep phenotypes5.000000e-06
GCST004131_74Inflammatory bowel disease2.000000e-07
GCST004133_52Ulcerative colitis4.000000e-11
GCST004562_105Waist circumference adjusted for body mass index1.000000e-07
GCST004562_135Waist circumference adjusted for body mass index8.000000e-08
GCST004562_228Waist circumference adjusted for body mass index5.000000e-08
GCST004562_29Waist circumference adjusted for body mass index9.000000e-08
GCST004562_52Waist circumference adjusted for body mass index2.000000e-08
GCST004563_10Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)6.000000e-08
GCST004563_112Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)4.000000e-07
GCST004563_191Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)2.000000e-07
GCST004563_249Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)7.000000e-07
GCST004563_91Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction)8.000000e-07
GCST004564_118Waist circumference adjusted for BMI in active individuals3.000000e-06
GCST004564_119Waist circumference adjusted for BMI in active individuals3.000000e-06
GCST004564_120Waist circumference adjusted for BMI in active individuals1.000000e-06
GCST004564_121Waist circumference adjusted for BMI in active individuals7.000000e-06
GCST004564_122Waist circumference adjusted for BMI in active individuals2.000000e-06
GCST006979_721Heel bone mineral density2.000000e-09
GCST007147_3Lateral ventricular volume in normal aging6.000000e-13
GCST007294_130Body fat distribution (trunk fat ratio)1.000000e-38
GCST007294_96Body fat distribution (trunk fat ratio)3.000000e-43
GCST007295_154Body fat distribution (leg fat ratio)4.000000e-37
GCST007295_18Body fat distribution (leg fat ratio)1.000000e-08
GCST007295_77Body fat distribution (leg fat ratio)3.000000e-40
GCST007692_82Chronic obstructive pulmonary disease4.000000e-09
GCST008152_83Weight3.000000e-06
GCST008163_204Height2.000000e-07
GCST008362_165Birth weight3.000000e-13

EFO canonical traits (18, from GWAS)

EFO IDTrait name
EFO:0007828daytime rest measurement
EFO:0007789BMI-adjusted waist circumference
EFO:0008002physical activity measurement
EFO:0009270heel bone mineral density
EFO:0008487lateral ventricle volume measurement
EFO:0004341body fat distribution
EFO:0004338body weight
EFO:0004344birth weight
EFO:0005939parental genotype effect measurement
EFO:0008344response to placebo
EFO:0010339FVC change measurement
EFO:0004346neuroimaging measurement
EFO:0006935thalamus volume
EFO:0008039BMI-adjusted hip circumference
EFO:0004980appendicular lean mass
EFO:0004587lymphocyte count
EFO:0005091monocyte count
EFO:0007985platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

ChemicalActions (top 5)PubMed papers
GSK-J4decreases expression1
triphenyl phosphatedecreases expression1
bisphenol Adecreases expression1
sodium arseniteincreases expression1
perfluorooctanoic acidincreases expression1
S-(1,2-dichlorovinyl)cysteineaffects cotreatment, decreases expression1
clothianidinincreases expression1
theaflavin-3,3’-digallateaffects expression1
Benzo(a)pyrenedecreases methylation, affects methylation1
Doxorubicinincreases expression1
Estradiolincreases expression1
Lipopolysaccharidesaffects cotreatment, decreases expression1
Valproic Acidincreases methylation1
Aflatoxin B1decreases methylation1
Gold Compoundsincreases expression1
Antirheumatic Agentsdecreases expression1
Particulate Matterdecreases expression1
Magnetite Nanoparticlesdecreases methylation1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

TrialPhaseStatusTitle
NCT00076362PHASE4COMPLETEDPediatric Hypothalamic Obesity
NCT00079547PHASE4COMPLETEDThe Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063PHASE4TERMINATEDLOSS- Louisiana Obese Subjects Study
NCT00134303PHASE4COMPLETEDTrial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936PHASE4COMPLETEDThe Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962PHASE4COMPLETEDComparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360PHASE4COMPLETEDThe Effect of Xenical on Weight and Risk Factors
NCT00176306PHASE4COMPLETEDLevofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450PHASE4COMPLETEDZonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504PHASE4COMPLETEDOral Contraceptives in the Metabolic Syndrome
NCT00229229PHASE4TERMINATEDComparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988PHASE4COMPLETEDA Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589PHASE4COMPLETEDExercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873PHASE4COMPLETEDCharacterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857PHASE4TERMINATEDA Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146PHASE4COMPLETEDOptimizing Body Composition for Function in Older Adults
NCT00319202PHASE4TERMINATEDClinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912PHASE4UNKNOWNLaparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287PHASE4COMPLETEDStudy to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054PHASE4COMPLETEDEffect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637PHASE4COMPLETEDDiet, Obesity and Genes (DiOGenes)
NCT00415688PHASE4COMPLETEDLifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641PHASE4COMPLETEDWeight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
NCT00440375PHASE4COMPLETEDEffects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00453557PHASE4COMPLETEDMechanism of Growth Hormone Effects on Adipose Tissue
NCT00456885PHASE4COMPLETEDThe Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
NCT00463112PHASE4COMPLETEDEffect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
NCT00512187PHASE4COMPLETEDModerate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00516919PHASE4COMPLETEDStudy of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00522470PHASE4COMPLETEDEffects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
NCT00537810PHASE4COMPLETEDTreatment of Binge Eating in Obese Patients in Primary Care
NCT00538486PHASE4COMPLETEDA Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
NCT00584389PHASE4TERMINATEDThe Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition
NCT00585182PHASE4COMPLETEDStudy to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
NCT00632840PHASE4COMPLETEDPharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00636142PHASE4COMPLETEDEffects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
NCT00675987PHASE4COMPLETEDA Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
NCT00694811PHASE4COMPLETEDEffects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)
NCT00699413PHASE4TERMINATEDSupplements for Controlling Resistance to Insulin
NCT00729963PHASE4COMPLETEDSibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 74

This page pulls from 74 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot